Skip to main navigation Skip to search Skip to main content

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Phamacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients

Project: Research

Project Details

StatusFinished
Effective start/end date10/9/19 → 10/31/23

Funding

  • Kedrion S.p.A.: $53,983.45